We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Safety, Pharmacokinetics, Biodistribution, and Diagnostic Performance of [18F]GP1 PET in Thromboembolism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02864810
Recruitment Status : Completed
First Posted : August 12, 2016
Last Update Posted : May 18, 2018
Information provided by (Responsible Party):
Asan Foundation

Brief Summary:
[18F]GP1 targets platelet GPIIb/IIIa receptor in thrombus. [18F]GP1 PET/CT imaging will noninvasively assess thrombus in whole body with good sensitivity with information of thrombus. Safety, pharmacokinetics, biodistribution, internal radiation dosimetry and diagnostic performance of [18F]GP1 will be assessed in all subjects.

Condition or disease Intervention/treatment Phase
Thromboembolism Drug: [18F]GP1 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Phase 1, Open-label, Non-randomized, Single Center Study to Assess Safety, Pharmacokinetics, Biodistribution, Internal Radiation Dosimetry and Diagnostic Performance of [18F]GP1 Positron Emission Tomography in Subjects With Venous or Arterial Thromboembolism
Actual Study Start Date : August 4, 2016
Actual Primary Completion Date : September 9, 2017
Actual Study Completion Date : September 9, 2017

Arm Intervention/treatment
Experimental: [18F]GP1 PET/CT imaging

Maximally 10 patients with deep vein thrombosis, pulmonary embolism, or arterial thromboembolism, respectively will be enrolled in the study (plus replacements for drop-outs).

Intravenous injection and PET/CT scanning of [18F]GP1

Drug: [18F]GP1
[18F]GP1 PET/CT imaging for detecting thromboembolism
Other Name: GP1

Primary Outcome Measures :
  1. Detection rate of thromboembolic focus/foci with [18F]GP1 PET/CT [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Quantitative assessment of [18F]GP1 uptake in thromboembolic focus/foci as measured by standardized uptake value (SUV) [ Time Frame: 6 months ]
  2. Biodistribution and radiation dosimetry of [18F]GP1 as measured by SUV [ Time Frame: 6 months ]
  3. Biodistribution and radiation dosimetry of [18F]GP1 as measured by radiation doses per organ (μGy/MBq). [ Time Frame: 6 months ]
  4. Pharmacokinetics of [18F]GP1 as measured by area under the curve [ Time Frame: 6 months ]
  5. Pharmacokinetics of [18F]GP1 as measured by Cmax [ Time Frame: 6 months ]
  6. Pharmacokinetics of [18F]GP1 as measured by Tmax [ Time Frame: 6 months ]
  7. Pharmacokinetics of [18F]GP1 as measured by percent fraction [ Time Frame: 6 months ]
  8. Safety of [18F]GP1 as measured by the number of participants with adverse events and significant changes in vital signs, electrocardiogram, physical examination and laboratory data that are related to treatment. [ Time Frame: 6 months ]
    Evaluation of safety of [18F]GP1

  9. Correlation of [18F]GP1 activity with fibrinogen and platelet glycoprotein IIb/IIIa and P-selectin expression. [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient is ≥ 19 years of age and male or female of any race/ethnicity.
  • Patient has signs or symptoms of acute DVT of the leg, acute PE or ATE; or had arterial intervention or surgery, such as endovascular abdominal aortic aneurysm repair preferably within 14 days prior to the planned study with [18F]GP1.
  • Patient has thromboembolic focus/foci confirmed by standard imaging modalities within 5 days prior to administration of [18F]GP1.
  • Patient has Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at time of screening.
  • Patient has clinical laboratory tests that are within the following ranges, determined within 7 days prior to administration of [18F]GP1:

    • White blood cell count ≥ 3.0 x 109/L;
    • Platelets ≥ 75.0 x 109/L;
    • ALT and AST ≤ 3.0 times upper limit of normal;
    • Bilirubin ≤ 1.5 times upper limit of normal; and
    • Serum creatinine ≤ 1.5 times upper limit of normal

Exclusion Criteria:

A patient will be excluded from this study if the patient does not fulfill the inclusion criteria, or if any of the following conditions are observed:

  • Patient or patient's legally acceptable representative does not provide written informed consent.
  • In case of acute DVT or PE, patient has a previous history of objectively diagnosed DVT or PE.
  • Patient had pretreatment with glycoprotein IIb/IIIa inhibitors within 15 days before the administration of [18F]GP1
  • Chemotherapy is scheduled to given to patient before or within 24 hours after administration of [18F]GP1.
  • Female patient is pregnant or nursing.
  • Patient has concurrent severe and/or uncontrolled and/or unstable medical disease other than cancer (e.g. congestive heart failure, acute myocardial infarction, severe pulmonary disease, chronic renal or hepatic disease which could compromise participation in the study) in the judgment of the investigator.
  • Patient is a relative of the investigator, student of the investigator or otherwise dependent.
  • Patient has been involved in another investigative clinical study involving administration of an investigational drug from preceding 4 weeks before to 24 hours after administration of [18F]GP1.
  • Patient has been previously included in this study.
  • Patient has any other condition or personal circumstances that, in the judgment of the investigator, might make collection of complete data difficult or impossible.
  • Additive-related precautions: This investigational product contains sodium bisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02864810

Layout table for location information
Korea, Republic of
Asan Foundation
Seoul, Korea, Republic of, 05505
Sponsors and Collaborators
Asan Foundation
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Asan Foundation
ClinicalTrials.gov Identifier: NCT02864810    
Other Study ID Numbers: GP1-1501
First Posted: August 12, 2016    Key Record Dates
Last Update Posted: May 18, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases